Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $411.2 million.

  • Coherus Oncology's Total Non-Current Liabilities fell 2706.79% to $411.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.2 million, marking a year-over-year decrease of 2706.79%. This contributed to the annual value of $551.2 million for FY2024, which is 3199.07% down from last year.
  • Latest data reveals that Coherus Oncology reported Total Non-Current Liabilities of $411.2 million as of Q3 2025, which was down 2706.79% from $302.9 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Total Non-Current Liabilities high stood at $842.7 million for Q1 2024, and its period low was $302.9 million during Q2 2025.
  • Its 5-year average for Total Non-Current Liabilities is $602.3 million, with a median of $582.6 million in 2021.
  • Per our database at Business Quant, Coherus Oncology's Total Non-Current Liabilities skyrocketed by 8271.39% in 2021 and then plummeted by 5857.84% in 2025.
  • Over the past 5 years, Coherus Oncology's Total Non-Current Liabilities (Quarter) stood at $580.9 million in 2021, then rose by 5.84% to $614.8 million in 2022, then skyrocketed by 31.83% to $810.5 million in 2023, then tumbled by 31.99% to $551.2 million in 2024, then decreased by 25.4% to $411.2 million in 2025.
  • Its last three reported values are $411.2 million in Q3 2025, $302.9 million for Q2 2025, and $523.2 million during Q1 2025.